1-(2,3,4-trihydroxy-phenyl)-pentan-1-one | 43043-25-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(2,3,4-trihydroxy-phenyl)-pentan-1-one
• 英文别名: 1-(2,3,4-Trihydroxy-phenyl)-pentan-1-on；1-(2,3,4-Trihydroxyphenyl)-1-pentanone；1-(2,3,4-trihydroxyphenyl)pentan-1-one
• CAS: 43043-25-0
• 化学式: C₁₁H₁₄O₄
• 分子量: 210.23
• InChiKey: REUQOHDZTHCRIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(2,3,4-trihydroxy-phenyl)-pentan-1-one 在 溴 、 溶剂黄146 作用下， 生成 1-(5-bromo-2,3,4-trihydroxy-phenyl)-pentan-1-one
  参考文献：
  名称：

  Compounds with Possible Effect on Polycythemia and Erythremia. I. Derivatives of Pyrogallol

  摘要：

  DOI：

  10.1021/jo50018a016
• 作为产物：
  描述：

  邻苯三酚 、 正戊酸 在 乙醚 、 三氟化硼 作用下， 生成 1-(2,3,4-trihydroxy-phenyl)-pentan-1-one
  参考文献：
  名称：

  The Spectrophotometric Examination of Some Derivatives of Pyrogallol and Phloroglucinol

  摘要：

  DOI：

  10.1021/ja01150a079

文献信息

• Alkyl Phenols. I. The 4-n-Alkylpyrogallols¹
  作者：Merrill C. Hart、E. H. Woodruff

  DOI：10.1021/ja01301a036

  日期：1936.10
• Synthesis, Antiproliferative, and c-Src Kinase Inhibitory Activities of 4-Oxo-4<i>H</i>-1-benzopyran Derivatives
  作者：Karam Chand、Rakesh K Tiwari、Sumit Kumar、Amir Nasrolahi Shirazi、Sweta Sharma、Erik V Van der Eycken、Virinder S Parmar、Keykavous Parang、Sunil K Sharma

  DOI：10.1002/jhet.2106

  日期：2015.3

  A new class of 4‐oxo‐4H‐1‐benzopyran derivatives were synthesized and their antiproliferative activity examined against a panel of three human cancer cell lines, that is, breast carcinoma (MDA‐MB‐468), ovarian adenocarcinoma (SK‐OV‐3), and colorectal adenocarcinoma (HT‐29). Two compounds, that is, 3‐hexyl‐7,8‐dihydroxy‐4‐oxo‐4H‐1‐benzopyran and (E)‐ethyl 3‐(7‐methoxy‐4‐oxo‐4H‐1‐benzopyran‐3‐yl)acrylate were found to be potent against all three cancer cell lines studied at 50 μM concentration. Also, the inhibitory potency of the compounds was evaluated against active Src kinase. A few of these compounds exhibited modest Src kinase inhibitory activity (IC50 = 52–57 μM). Structure‐activity relationship studies with respect to the nature and position of substituents on the lead compounds could be further exploited for the design and development of more potent antiproliferative agents and/or Src kinase inhibitors.